Antiangiogenic therapy in renal cell carcinoma: a plethora of choices

Affiliations

Comment

Cora N Sternberg. Nat Clin Pract Urol. 2008 Aug.

. 2008 Aug;5(8):422-3.

doi: 10.1038/ncpuro1157. Epub 2008 Jul 8.

¹ Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, Circonvallazione, Gianicolense 87, Rome 00152, Italy. cstern@mclink.it

No abstract available

Comment on

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Escudier B, et al. Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7. Lancet. 2007. PMID: 18156031 Clinical Trial.